Yonhap Infomax NewsJun 26, 2025
GC Pharma and Celltrion posted the lowest ROE among major South Korean pharmaceutical and biotech firms, while Samsung Biologics and Chong Kun Dang recorded the lowest dividend payout ratios, highlighting key value-up challenges in the sector.
#YonhapInfomax #ROE #GCPharma #Celltrion #DividendPayout #SamsungBiologics #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=69406
[Pharmaceutical & Bio Value-Up①] GC Pharma, Celltrion Post Lowest ROE

GC Pharma and Celltrion posted the lowest ROE among major South Korean pharmaceutical and biotech firms, while Samsung Biologics and Chong Kun Dang recorded the lowest dividend payout ratios, highlighting key value-up challenges in the sector.

Yonhap Infomax
Yonhap Infomax NewsApr 25, 2025
GC Holdings' Chairman Heo Il-seop acquires 40,000 shares, increasing stake to 12.28%, while GC Pharma's Director Heo Eun-chul purchases 23,107 shares, raising ownership to 2.68%
#YonhapInfomax #GCHoldings #ShareAcquisition #ChairmanHeoIlSeop #OwnershipStake #GCPharma #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=60473
Chairman Heo Il-seop Acquires 40,000 Shares of GC Holdings in Market

GC Holdings' Chairman Heo Il-seop acquires 40,000 shares, increasing stake to 12.28%, while GC Pharma's Director Heo Eun-chul purchases 23,107 shares, raising ownership to 2.68%

Yonhap Infomax
Yonhap Infomax NewsApr 17, 2025
GC Pharma selected for KDCA's mRNA vaccine development project, aiming to secure domestic platform with 505.2 billion won investment by 2028
#YonhapInfomax #GCPharma #MRNAVaccine #KDCA #VaccineDevelopment #PandemicPreparedness #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=59197
GC Pharma Selected for KDCA's 'mRNA Vaccine Development Support Project'

GC Pharma selected for KDCA's mRNA vaccine development project, aiming to secure domestic platform with 505.2 billion won investment by 2028

Yonhap Infomax
Yonhap Infomax NewsMar 18, 2025
GC Pharma's US affiliate Curevo Vaccine secures $110 million in Series B funding for shingles vaccine development, led by European VC Medicxi with participation from major healthcare investors.
#YonhapInfomax #CurevoVaccine #SeriesBFunding #ShinglesVaccine #GCPharma #ClinicalTrials #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=54474
GC Pharma's US Affiliate Curevo Secures $110 Million Series B Investment

GC Pharma's US affiliate Curevo Vaccine secures $110 million in Series B funding for shingles vaccine development, led by European VC Medicxi with participation from major healthcare investors.

Yonhap Infomax